{"slug":"cartalax","seoKey":"cartalax","displayName":"Cartalax","codes":["T-31"],"synonyms":["Ala-Glu-Asp","AED","AED peptide","T-31 peptide","H-Ala-Glu-Asp-OH","L-alanyl-L-glutamyl-L-aspartic acid","alanyl-glutamyl-aspartic acid (the NLM MeSH supplementary concept heading)","Kartalax / Карталакс (Russian trade name)"],"legalClass":"research_chemical","identifiers":{"cas":"85806-95-7","pubchemCid":87815447,"inchikey":"KXEVYGKATAMXJJ-ACZMJKKPSA-N","formula":"C12H19N3O8","molecularWeight":333.29,"sequence":"AED"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved and not registered as a substance. Four federal queries returned no match on 2026-09-10: no drug label, no adverse event report, no entry in the labelling database and no record in the substance registration system, which is why there is no UNII. The substance has also never been nominated for the compounding bulks list; the structurally adjacent dipeptide alanyl-glutamine sits in category 1 at exactly the alphabetical position where an entry would appear, so this is an absence and not an oversight.","source":"https://api.fda.gov/drug/label.json?search=openfda.substance_name:%22Cartalax%22"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no assessment report and no pharmacopoeial monograph. The register itself could not be queried on 2026-09-10 because the site returned an authorisation error and an antibot page, so this is a negative finding drawn from the absence of any entry in every other authority database checked and from the absence of any clinical development programme.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=cartalax"},{"market":"DE","status":"not_approved","note":"Neither a national nor an EU marketing authorisation exists, so an injectable preparation is not a marketable medicinal product and may not be imported or dispensed. The substance is also not named in the schedule to the Anti-Doping Act, and no catch-all position of that schedule covers a cartilage tripeptide; the full text was checked on 2026-09-10. Sporting rules are unaffected by that.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No marketing authorisation known. The product register returned only the JavaScript shell of its search page on 2026-09-10 and a control query with an approved active ingredient produced an identical response, so the negative finding could not be verified positively. It rests on the absence of any entry elsewhere and on the absence of any clinical development.","source":"https://products.mhra.gov.uk/search/?search=cartalax"},{"market":"AU","status":"not_approved","note":"Not named in the Poisons Standard; the full text of the June 2026 instrument was searched on 2026-09-10 for the trade name, the transliteration and the sequence without a hit. There is no generic peptide position in that instrument, and short peptides are listed by name where they are scheduled, so this is a real absence. Absence of a listing is not a clearance: unregistered therapeutic goods remain subject to registration requirements, and the registry itself was not programmatically queryable.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"No marketing authorisation and no entry in the drug product database; queries for the trade name and for the sequence returned empty results on 2026-09-10, while a control query for an authorised product returned its identification number, so the interface was working.","source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en&type=json&brandname=cartalax"},{"market":"CH","status":"not_approved","note":"No marketing authorisation known. No direct register query was possible on 2026-09-10, so this is a negative finding drawn from the absence of an authorisation in every market that could be checked and from the absence of any clinical development programme.","source":"https://www.swissmedicinfo.ch/"}],"devStage":"preclinical","strongestEvidence":"animal","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/87815447"],"lastVerified":"2026-09-10","version":"1.0","published":true,"locale":"en","title":"Cartalax: what the studies show, status and safety","summary":"Cartalax is a synthetic chain of three amino acids, worked out in St Petersburg from an animal cartilage extract. Not one study in people exists, registered or published. The cartilage claim rests on a 2008 patent and three papers from 2023, two cell experiments and a review, all from the group that holds the patent. It is approved nowhere, and it is banned in sport at all times.","updated":"2026-09-10","url":"https://mypep.app/peptides/cartalax"}